Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has been given a consensus recommendation of “Buy” by the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $26.40.

Several analysts have recently weighed in on CNCE shares. Zacks Investment Research downgraded shares of Concert Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Monday, May 8th. Aegis reaffirmed a “buy” rating and issued a $25.00 target price on shares of Concert Pharmaceuticals in a report on Monday, June 12th. ValuEngine raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $30.00 target price (down previously from $31.00) on shares of Concert Pharmaceuticals in a report on Monday, July 10th. Finally, BidaskClub downgraded shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th.

Several hedge funds have recently modified their holdings of CNCE. State Street Corp increased its stake in shares of Concert Pharmaceuticals by 3.8% in the fourth quarter. State Street Corp now owns 349,505 shares of the biotechnology company’s stock valued at $3,594,000 after buying an additional 12,690 shares during the last quarter. FMR LLC boosted its stake in shares of Concert Pharmaceuticals by 17.7% in the fourth quarter. FMR LLC now owns 100,000 shares of the biotechnology company’s stock valued at $1,029,000 after buying an additional 15,056 shares during the period. Highbridge Capital Management LLC boosted its stake in shares of Concert Pharmaceuticals by 46.4% in the fourth quarter. Highbridge Capital Management LLC now owns 15,677 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 4,967 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Concert Pharmaceuticals by 22.7% in the first quarter. Fisher Asset Management LLC now owns 44,363 shares of the biotechnology company’s stock valued at $757,000 after buying an additional 8,200 shares during the period. Finally, Hikari Power Ltd bought a new stake in shares of Concert Pharmaceuticals during the first quarter valued at approximately $200,000. 62.80% of the stock is currently owned by institutional investors and hedge funds.

Shares of Concert Pharmaceuticals (NASDAQ CNCE) traded up 0.72% on Friday, hitting $14.01. 118,235 shares of the company’s stock were exchanged. The stock’s market cap is $317.84 million. Concert Pharmaceuticals has a 12-month low of $7.11 and a 12-month high of $19.11. The company’s 50-day moving average price is $14.27 and its 200 day moving average price is $13.89.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.04. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.20 million. Concert Pharmaceuticals had a negative net margin of 60,681.70% and a negative return on equity of 61.98%. On average, equities analysts predict that Concert Pharmaceuticals will post ($2.48) earnings per share for the current fiscal year.

WARNING: “Concert Pharmaceuticals, Inc. (CNCE) Receives Average Rating of “Buy” from Analysts” was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/12/concert-pharmaceuticals-inc-cnce-receives-average-rating-of-buy-from-analysts.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Analyst Recommendations for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.